Preoperative cardiac risk assessment

Am Fam Physician. 2002 Nov 15;66(10):1889-96.

Abstract

Heart disease is the leading cause of mortality in the United States. An important subset of heart disease is perioperative myocardial infarction, which affects approximately 50,000 persons each year. The American College of Cardiology (ACC) and American Heart Association (AHA) have coauthored a guideline on preoperative cardiac risk assessment, as has the American College of Physicians (ACP). The ACC/AHA guideline uses major, intermediate, and minor clinical predictors to stratify patients into different cardiac risk categories. Patients with poor functional status or those undergoing high-risk surgery require further risk stratification via cardiac stress testing. The ACP guideline also starts by screening patients for clinical variables that predict perioperative cardiac complications. However, the ACP did not feel there was enough evidence to support poor functional status as a significant predictor of increased risk. High-risk patients would sometimes merit preoperative cardiac catheterization by the ACC/AHA guideline, while the ACP version would reserve catheterization only for those who were candidates for cardiac revascularization independent of their noncardiac surgery. A recent development in prophylaxis of surgery-related cardiac complications is the use of beta blockers perioperatively for patients with cardiac risk factors.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage
  • Anesthesia / methods
  • Coronary Disease / complications
  • Coronary Disease / diagnosis
  • Elective Surgical Procedures / adverse effects
  • Guideline Adherence
  • Heart Diseases / complications*
  • Heart Diseases / diagnosis*
  • Humans
  • Postoperative Complications / etiology*
  • Postoperative Complications / prevention & control*
  • Practice Guidelines as Topic
  • Predictive Value of Tests
  • Preoperative Care / methods*
  • Prognosis
  • Risk Assessment
  • Risk Factors

Substances

  • Adrenergic beta-Antagonists